Showing results (61-70 of 77) with videos related to
Sort By:
Pageof 8
Gynecologic Oncology|June 1, 2014
Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancerMonica N Schointuch, Timothy P Gilliam, Jessica E Stine, et al.Chemical Communications (Cambridge, England)|January 24, 2015
Enzymatic cleavage of uracil-containing single-stranded DNA linkers for the efficient release of affinity-selected circulating tumor cellsSoumya V Nair, Małgorzata A Witek, Joshua M Jackson, et al.Oncotarget|October 28, 2015
The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancerJessica E Stine, Hui Guo, Xiugui Sheng, et al.Endocrine-Related Cancer|June 6, 2015
Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathwayLingqin Yuan, Xiugui Sheng, Adam K Willson, et al.Journal of Hematology & Oncology|January 30, 2015
Evaluation of the anti-tumor effects of lactate dehydrogenase inhibitor galloflavin in endometrial cancer cellsXiaoyun Han, Xiugui Sheng, Hannah M Jones, et al.Cancer Chemotherapy and Pharmacology|January 30, 2016
Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancerHugh Giovinazzo, Parag Kumar, Arif Sheikh, et al.Cancer Medicine|December 7, 2019
Jupiter microtubule-associated homolog 1 (JPT1): A predictive and pharmacodynamic biomarker of metformin response in endometrial cancersNicholas W Bateman, Pang-Ning Teng, Erica Hope, et al.Gynecologic Oncology|July 12, 2025
Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therapy Consortium (ECMT2)Sarah S Lee, Angeles Alvarez Secord, Steven Friedman, et al.Gynecologic Oncology|January 8, 2017
Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinomaStuart R Pierce, Jessica E Stine, Paola A Gehrig, et al.Journal of Experimental & Clinical Cancer Research : CR|February 9, 2021
Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancerStuart R Pierce, Ziwei Fang, Yajie Yin, et al.Pageof 8